PPARG and neoplasm: Treatment with caspase-1 inhibitors (YVAD, VADs, and NCX-4016) suppressed lipid accumulation and primary tumor growth for targeting the caspase-1/PPARγ/MCAD pathway in TAM differentiation (123).